436095-41-9

Upstream product

• 1159282-08-2 N-[2-(tert-butyldiphenylsilanyloxy)-ethyl]-2-chloro-5-nitro-benzenesulfonamide 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 129018-68-4 2-chloro-N-(2-hydroxyethyl)-5-nitrobenzenesulfonamide 
• 22184-93-6 2-(3-nitrophenylsulfonylamino)ethanol 
• 141-43-5 ethanolamine 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Downstream Products

• 1159282-07-1 N-(2-hydroxyethyl)-3-(2,4,6-trichlorophenylamino)benzenesulfonamide 
• 70566-40-4 sulphuric acid mono-N-(3-aminophenylsulphonyl)-2-aminoethyl ester 

Relevant academic research and scientific papers

POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF

Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs wherein: Ar1 and Ar2=aryl or heteroaryl; a=0 to 5; R1=alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamin

POTASSIUM ION CHANNEL MODULATORS and USES THEREOF

Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalky

PURINE DERIVATIVES

Purine derivatives of Formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.

Pyrazole compounds

Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.